MBA MSc - Antibe Therapeutics Founder Chair
| ATBPF Stock | USD 0.22 0.00 0.00% |
Insider
MBA MSc is Founder Chair of Antibe Therapeutics
| Age | 65 |
| Phone | 416 922 3460 |
| Web | https://www.antibethera.com |
Antibe Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.1642) % which means that it has lost $0.1642 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.4013) %, meaning that it generated substantial loss on money invested by shareholders. Antibe Therapeutics' management efficiency ratios could be used to measure how well Antibe Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| Patrick Johnson | Vertiv Holdings Co | 49 | |
| Chris Malachowsky | NVIDIA | N/A | |
| Raanan Agus | Vertiv Holdings Co | 50 | |
| Andrea James | Axon Enterprise | N/A | |
| Joseph Dokkum | Vertiv Holdings Co | 66 | |
| Rainer Stiller | Vertiv Holdings Co | N/A | |
| Prof Dally | NVIDIA | 63 | |
| Andrew Cole | Vertiv Holdings Co | 54 | |
| Edward Monser | Vertiv Holdings Co | 70 | |
| Alfonso Villanueva | PayPal Holdings | N/A | |
| Brittany Bagley | Axon Enterprise | 41 | |
| Jason Forcier | Vertiv Holdings Co | 48 | |
| Stephanie Gill | Vertiv Holdings Co | 49 | |
| Edward CFA | Nasdaq Inc | N/A | |
| Luke Larson | Axon Enterprise | 43 | |
| Jim Zito | Axon Enterprise | 43 | |
| Erin Dowd | Vertiv Holdings Co | 53 | |
| Joshua Isner | Axon Enterprise | 38 | |
| Roger Fradin | Vertiv Holdings Co | 67 | |
| Emily Spurling | Nasdaq Inc | N/A | |
| John Zecca | Nasdaq Inc | 56 | |
Management Performance
| Return On Equity | -0.4 | |||
| Return On Asset | -0.16 |
Antibe Therapeutics Leadership Team
Elected by the shareholders, the Antibe Therapeutics' board of directors comprises two types of representatives: Antibe Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Antibe. The board's role is to monitor Antibe Therapeutics' management team and ensure that shareholders' interests are well served. Antibe Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Antibe Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Philip Stern, VP Communications | ||
| Ana Stegic, Director Operations | ||
| LLB JD, CEO and President | ||
| MEng CFA, Chief Officer | ||
| MBA MSc, Founder Chair | ||
| MBA DO, Chief Officer | ||
| David Vaughan, Chief Devel. Officer | ||
| MBA MBA, Chief Officer | ||
| Christina BBA, VP Relations |
Antibe Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Antibe Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.4 | |||
| Return On Asset | -0.16 | |||
| Current Valuation | (19.98 M) | |||
| Shares Outstanding | 52.14 M | |||
| Shares Owned By Insiders | 7.79 % | |||
| Price To Earning | (1.67) X | |||
| Price To Book | 0.61 X | |||
| Price To Sales | 2.96 X | |||
| Gross Profit | 3.55 M | |||
| EBITDA | (25.14 M) |
Currently Active Assets on Macroaxis
Other Information on Investing in Antibe Pink Sheet
Antibe Therapeutics financial ratios help investors to determine whether Antibe Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Antibe with respect to the benefits of owning Antibe Therapeutics security.